




Fig. 1




Fig. 2




Fig. 3




Fig. 4

| Procedure                                     | Screening      | Baseline 1 / 2          | Treatment period 1 / 2 |                    |                     |                                      | Follow-up                                                            | Notes |
|-----------------------------------------------|----------------|-------------------------|------------------------|--------------------|---------------------|--------------------------------------|----------------------------------------------------------------------|-------|
| Study visit (V)                               | V1             | V2 /<br>V6 <sup>a</sup> | V3 /<br>V7             | V4 /<br>V8         | V5 /<br>V9<br>(EOT) | V10 (EOS)                            |                                                                      |       |
|                                               | D-29<br>to D-2 | D-1 /<br>D28            | D7 /<br>D35            | D14 /<br>D42       | D21 /<br>D49        | D56<br>(7±2 days<br>after last dose) |                                                                      |       |
| Treatment days                                |                | -1                      | 7±1                    | 14±1               | 21±1                |                                      |                                                                      |       |
| Visit type                                    | Site           | Site                    | Phone <sup>b</sup>     | Phone <sup>b</sup> | Site                | Site                                 |                                                                      |       |
| Informed consent                              | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Eligibility criteria                          | X              | X                       |                        |                    |                     |                                      |                                                                      |       |
| Demography                                    | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Height and weight                             | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Medical/surgical history                      | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Current medical condition                     | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Substance use/drug screen                     | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| HIV, hepatitis B/C serology                   | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Serum pregnancy test                          | X              |                         |                        |                    |                     |                                      | WOCBP only                                                           |       |
| Urine pregnancy test                          |                | X                       |                        |                    | X                   | X                                    | WOCBP only                                                           |       |
| Safety laboratory tests                       | X              | X                       |                        |                    | X                   | X                                    | refer to Appendix 2                                                  |       |
| Full physical examination                     | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| Brief physical examination                    |                | X                       |                        |                    | X                   | X                                    |                                                                      |       |
| AE/SAE review                                 | X              | X                       | X                      | X                  | X                   | X                                    |                                                                      |       |
| C-SSRS baseline                               | X              |                         |                        |                    |                     |                                      |                                                                      |       |
| C-SSRS since last visit/call                  |                | X                       | X                      | X                  | X                   | X                                    |                                                                      |       |
| Concomitant medication review                 | X              | X                       | X                      | X                  | X                   | X                                    |                                                                      |       |
| 12-lead ECG                                   | X              | X                       |                        |                    | X                   | X                                    |                                                                      |       |
| Randomisation                                 |                | X                       |                        |                    |                     |                                      |                                                                      |       |
| Study intervention or matching placebo dosing |                |                         | 400 mg bid for 21 days |                    |                     |                                      | dosing at home, except afternoon doses on visit days (V5/V9) at site |       |

Fig. 5A

| Procedure                                                                            | Screening      | Baseline 1 / 2          | Treatment period 1 / 2 |                    |                     |                                      | Follow-up                            | Notes |
|--------------------------------------------------------------------------------------|----------------|-------------------------|------------------------|--------------------|---------------------|--------------------------------------|--------------------------------------|-------|
| Study visit (V)                                                                      | V1             | V2 /<br>V6 <sup>a</sup> | V3 /<br>V7             | V4 /<br>V8         | V5 /<br>V9<br>(EOT) | V10 (EOS)                            |                                      |       |
|                                                                                      | D-29<br>to D-2 | D-1 /<br>D28            | D7 /<br>D35            | D14 /<br>D42       | D21 /<br>D49        | D56<br>(7±2 days<br>after last dose) |                                      |       |
| Treatment days                                                                       |                | -1                      | 7±1                    | 14±1               | 21±1                |                                      |                                      |       |
| Visit type                                                                           | Site           | Site                    | Phone <sup>b</sup>     | Phone <sup>b</sup> | Site                | Site                                 |                                      |       |
| Study intervention dispensation                                                      |                | X                       |                        |                    |                     |                                      | with dosing diary                    |       |
| Compliance check                                                                     |                |                         |                        |                    | X                   |                                      | per returned doses and diary entries |       |
| MFEM-32                                                                              | X              |                         |                        |                    |                     |                                      |                                      |       |
| RNS (CMAP decrement) <sup>Error!</sup><br><small>Reference source not found.</small> | X              |                         |                        |                    |                     |                                      |                                      |       |
| INQoL                                                                                |                | X                       |                        |                    |                     | X                                    |                                      |       |
| FSS                                                                                  |                | X                       |                        |                    |                     | X                                    | over the last 7 days                 |       |
| 6MWT                                                                                 | X              | X                       |                        |                    | X                   |                                      | approximately 2 hours post-dose      |       |
| PK blood sample                                                                      |                |                         |                        |                    | X                   |                                      | after the 6MWT                       |       |
| Revised Hammersmith scale                                                            |                | X                       |                        |                    | X                   |                                      |                                      |       |
| Dynamometry                                                                          |                | X                       |                        |                    | X                   |                                      |                                      |       |
| ESNHPT                                                                               |                | X                       |                        |                    | X                   |                                      |                                      |       |
| sfEMG                                                                                |                | X                       |                        |                    | X                   |                                      | selected sites, only                 |       |
| Vital signs                                                                          | X              | X                       |                        |                    | X                   | X                                    | X                                    |       |

Fig. 5B